GRCE insider trading
NasdaqCM HealthcareGrace Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Company website: www.gracetx.com
GRCE insider activity at a glance
FilingIQ tracks 12 insider transactions for GRCE in filings since Aug 19, 2026. The most recent transaction is dated Oct 5, 2026.
Across the full history, 12 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GRCE insider trades is 52.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GRCE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for GRCE?
- FilingIQ tracks 12 Form 4 insider transactions for GRCE (Grace Therapeutics, Inc.), covering filings from Aug 19, 2026 onwards. 12 of those are dated within the last 90 days.
- Are GRCE insiders net buyers or net sellers?
- Across the full Form 4 history for GRCE, 12 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GRCE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is GRCE in?
- Grace Therapeutics, Inc. (GRCE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $70.86M.
Methodology & sources
Every GRCE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.